Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Current Opinion in Gastroenterology|January 16, 2022
The gut-liver axis in cholangiopathies: focus on bile acid based pharmacological treatmentMarica Cariello, Raffaella M Gadaleta, Antonio MoschettaNuclear Receptor Signaling|March 9, 2011
Deciphering the nuclear bile acid receptor FXR paradigmSalvatore Modica, Raffaella M Gadaleta, Antonio MoschettaMolecular Aspects of Medicine|February 8, 2025
Disentangling the nutrition-microbiota liaison in inflammatory bowel diseaseMarilina Florio, Lucilla Crudele, Fabio Sallustio, et al.International Journal of Molecular Sciences|September 19, 2018
Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker IdentificationBjoern Titz, Raffaella M Gadaleta, Giuseppe Lo Sasso, et al.Biochimica Et Biophysica Acta|April 20, 2010
Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal diseaseRaffaella M Gadaleta, Saskia W C van Mil, Bas Oldenburg, et al.Plos One|November 29, 2012
Pharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn's colitisFiona D M van Schaik, Raffaella M Gadaleta, Frank G Schaap, et al.Biochimica Et Biophysica Acta|May 5, 2011
Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-κB signaling in the intestineRaffaella M Gadaleta, Bas Oldenburg, Ellen C L Willemsen, et al.Gut|January 19, 2011
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel diseaseRaffaella M Gadaleta, Karel J van Erpecum, Bas Oldenburg, et al.Plos One|September 3, 2011
Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel diseaseRian M Nijmeijer, Raffaella M Gadaleta, Saskia W C van Mil, et al.Pageof 1